Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MTNB Stock Forecast 2025-2026
$0.67
Current Price
$3.41M
Market Cap
Buy 0
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to MTNB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
MTNB Price Momentum
+19.6%
1 Week Change
+24.1%
1 Month Change
-92.5%
1 Year Change
+31.4%
Year-to-Date Change
-93.1%
From 52W High of $9.70
+41.1%
From 52W Low of $0.47
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Matinas (MTNB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MTNB and similar high-potential opportunities.
Latest MTNB Stock Price Targets & Analyst Predictions
MTNB has shown a year-to-date change of 31.4% and a 1-year change of -92.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MTNB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MTNB Analyst Ratings
0
Buy
2
Hold
0
Sell
MTNB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.67
Latest MTNB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MTNB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2024 | Maxim Group | Jason McCarthy | Hold | Downgrade | $0.00 |
| Oct 11, 2023 | BTIG | Julian Harrison | Buy | Reinstates | $3.00 |
| Jan 31, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $3.00 |
| Aug 13, 2020 | Aegis Capital | Buy | Maintains | $3.50 | |
| Jan 27, 2020 | Piper Sandler | Overweight | Initiates | $0.00 | |
| Jan 24, 2020 | SunTrust Robinson Humphrey | Buy | Initiates | $0.00 | |
| Jun 26, 2019 | H.C. Wainwright | Buy | Initiates | $0.00 | |
| Jun 26, 2019 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| May 17, 2019 | BTIG Research | Buy | Initiates | $0.00 | |
| May 17, 2019 | BTIG | Buy | Initiates | $0.00 | |
| Feb 11, 2019 | Roth Capital | Buy | Initiates | $0.00 | |
| Nov 13, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $5.00 |
| Aug 13, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $2.00 |
| Jul 10, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $3.00 |
| Nov 1, 2016 | Aegis Capital | Buy | Initiates | $0.00 |
Matinas Biopharma Holdings Inc. (MTNB) Competitors
The following stocks are similar to Matinas based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MTNB
Matinas BioPharma
mkt cap
3.03M
Matinas Biopharma Holdings Inc. (MTNB) Financial Data
Matinas Biopharma Holdings Inc. has a market capitalization of $3.41M with a P/E ratio of -0.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -180.7%.
Valuation Metrics
Market Cap
$3.41M
Enterprise Value
$-981,720
P/E Ratio
-0.1x
PEG Ratio
-0.2x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+213.7%
Current Ratio
3.0x
Debt/Equity
38.1x
ROE
-180.7%
ROA
-66.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Matinas Biopharma Holdings Inc. (MTNB) Business Model
About Matinas Biopharma Holdings Inc.
What They Do
Develops innovative therapeutics for unmet medical needs.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, focusing on the development of lipid nano-crystal delivery technology. This technology enhances the bioavailability and efficacy of drugs, particularly targeting infectious diseases and rare disorders. Revenue is generated through partnerships, licensing agreements, and potential future sales of its advanced therapeutic solutions.
Additional Information
Matinas Biopharma is positioned within the biotechnology sector, directly impacting the healthcare and pharmaceutical industries. Its proprietary technology aims to reformulate drug delivery methods, potentially improving treatment outcomes and accessibility for patients.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
3
CEO
Mr. Jerome D. Jabbour J.D.
Country
United States
IPO Year
2014
Website
www.matinasbiopharma.comMatinas Biopharma Holdings Inc. (MTNB) Latest News & Analysis
Latest News
Quick Summary
Matinas BioPharma appointed Keith Murphy and Edward Neugeboren as independent directors, effective March 11, 2025.
Why It Matters
The addition of experienced biotech leaders to Matinas BioPharma's Board may enhance strategic direction, improve governance, and boost investor confidence, potentially impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. has secured a $3.3 million investment by agreeing to sell 3,300 shares of Series C Convertible Preferred Stock and warrants to investors.
Why It Matters
Matinas BioPharma's new securities deal raises $3.3 million, potentially enhancing liquidity and funding for operations, which could impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. has appointed Evelyn D'An as an independent director and Chair of the Audit Committee, effective February 5, 2025.
Why It Matters
Evelyn D'An's appointment enhances governance and oversight at Matinas BioPharma, potentially boosting investor confidence and influencing stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Matinas BioPharma Receives NYSE Noncompliance Notice
3 months ago
Quick Summary
Matinas BioPharma Holdings, Inc. (MTNB) received a notice from NYSE American on January 6, 2025, for not meeting listing standards due to the failure to hold its annual stockholders meeting.
Why It Matters
Matinas BioPharma's failure to hold its annual meeting risks delisting from NYSE American, potentially impacting stock liquidity and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma has terminated negotiations for global rights to MAT2203, leading to an 80% workforce reduction and cessation of product development to conserve cash.
Why It Matters
The termination of the partnership and drastic workforce reduction signal severe financial distress for Matinas BioPharma, likely leading to decreased investor confidence and potential stock price decline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. (NYSE:MTNB) held its Q2 2024 earnings conference call on August 14, 2024, featuring CEO Jerry Jabbour and CFO Keith Kucinski, among others.
Why It Matters
The earnings call provides insights into Matinas BioPharma's financial health and strategic direction, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About MTNB Stock
What is Matinas Biopharma Holdings Inc.'s (MTNB) stock forecast for 2025?
Analyst forecasts for Matinas Biopharma Holdings Inc. (MTNB) are not currently available. The stock is trading at $0.67.
Is MTNB stock a good investment in 2025?
According to current analyst ratings, MTNB has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MTNB stock?
Price predictions from Wall Street analysts for MTNB are not currently available. The stock is trading at $0.67.
What is Matinas Biopharma Holdings Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, focusing on the development of lipid nano-crystal delivery technology. This technology enhances the bioavailability and efficacy of drugs, particularly targeting infectious diseases and rare disorders. Revenue is generated through partnerships, licensing agreements, and potential future sales of its advanced therapeutic solutions.
What is the highest forecasted price for MTNB Matinas Biopharma Holdings Inc.?
Price targets from Wall Street analysts for MTNB are not currently available. The stock is trading at $0.67.
What is the lowest forecasted price for MTNB Matinas Biopharma Holdings Inc.?
Price targets from Wall Street analysts for MTNB are not currently available. The stock is trading at $0.67.
What is the overall MTNB consensus from analysts for Matinas Biopharma Holdings Inc.?
The overall analyst consensus for MTNB is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell.
How accurate are MTNB stock price projections?
Stock price projections, including those for Matinas Biopharma Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 8:39 PM UTC